井寺制药(IDRA)

chuminhua2022-05-18 15:01

5月18日，Idera Pharmaceuticals 的股价上涨了 61%，此前该公司表示，一项合成 TLR-9 激动剂 tilsotolimod 治疗黑色素瘤的IIT试验在中期分析显示达到主要终点后提前停止。研究人员 Tanja de Gruijl 表示，II 期 INTRIM 1 研究的结果“表明在切除部位施用 tilsotolimod 可降低肿瘤阳性淋巴结的范围...查看全文

当期报告

井寺制药(IDRA)2023-01-13 21:36

$井寺制药(IDRA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001104659-23-003629  Act: 34  Size: 375 KB 网页链接查看全文

持股变动声明

井寺制药(IDRA)2023-01-13 09:06

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000919  Size: 4 KB 网页链接查看全文

当期报告

井寺制药(IDRA)2023-01-18 06:33

$井寺制药(IDRA)$ 8-K Current report, items 5.03, 7.01, 8.01, and 9.01 Accession Number: 0001104659-23-004326  Act: 34  Size: 780 KB 网页链接查看全文

当期报告

井寺制药(IDRA)2023-01-11 21:36

$井寺制药(IDRA)$ 8-K Current report, item 8.01 Accession Number: 0001104659-23-002936  Act: 34  Size: 199 KB 网页链接查看全文

持股变动声明

井寺制药(IDRA)2023-01-11 10:21

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000764  Size: 6 KB 网页链接查看全文

持股变动声明

井寺制药(IDRA)2023-01-11 10:21

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000766  Size: 6 KB 网页链接查看全文

持股变动声明

井寺制药(IDRA)2023-01-11 10:21

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000765  Size: 6 KB 网页链接查看全文

持股变动声明

井寺制药(IDRA)2021-10-05 08:48

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-21-122658  Size: 4 KB 网页链接查看全文

员工持股计划

井寺制药(IDRA)2022-12-23 06:27

$井寺制药(IDRA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-22-129602  Act: 33  Size: 154 KB 网页链接查看全文

美东时间 2011-08-11 21:30 Q2 2011 Idera Pharmaceuticals Inc Earnings Release

美东时间 2011-06-29 22:30 Idera Pharmaceuticals Inc at Biotechnology Industry Organization International Convention

当期报告

$井寺制药(IDRA)$ 8-K Current report, items 5.03, 7.01, 8.01, and 9.01 Accession Number: 0001104659-23-004326  Act: 34  Size: 780 KB 网页链接

当期报告

$井寺制药(IDRA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001104659-23-003629  Act: 34  Size: 375 KB 网页链接

持股变动声明

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000919  Size: 4 KB 网页链接

当期报告

$井寺制药(IDRA)$ 8-K Current report, item 8.01 Accession Number: 0001104659-23-002936  Act: 34  Size: 199 KB 网页链接

持股变动声明

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000764  Size: 6 KB 网页链接

持股变动声明

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000765  Size: 6 KB 网页链接

持股变动声明

$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000766  Size: 6 KB 网页链接

员工持股计划

$井寺制药(IDRA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-22-129602  Act: 33  Size: 154 KB 网页链接

当期报告「修正」

$井寺制药(IDRA)$ 8-K/A [Amend] Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-125903  Act: 34  Size: 228 KB 网页链接

股东委托书协议

$井寺制药(IDRA)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-22-125528  Act: 34  Size: 5 MB 网页链接